TNFAIP6

Across TCGA pan-cancer cohorts, TNFAIP6 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TNFAIP6 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TNFAIP6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNFAIP6 expression acts as an unfavorable survival marker.

LUAD, HNSC, and SCLC are the cancer types where TNFAIP6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.261	0.792	<.001	27	view →
HNSC	OS	Median	All	0.246	0.688	.010	21	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
COAD	OS	Median	All	0.470	0.804	.009	9	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TNFAIP6–LUAD (DFS)

Open the LUAD breakdown →